TET enzyme driven epigenetic reprogramming in early embryos and its implication on long-term health.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms without new clinical or quantitative human data.
PubMed 39149518 · doi:10.3389/fcell.2024.1358649
What was done
This is a narrative review synthesizing current knowledge on TET family enzyme-mediated epigenetic reprogramming during mammalian early embryogenesis. The review describes dynamic DNA methylation and histone modifications prior to zygotic genome activation, the distinct regulation of paternal versus maternal genomes, and the implications of these pathways for clinical disorders and assisted reproductive technologies.
What was found
The abstract reports qualitative mechanistic descriptions and provides no quantitative data. TET family enzymes (specifically TET3) oxidize paternal 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) to lower paternal DNA methylation globally across mammalian species. The maternal genome is primarily protected from TET3-mediated oxidation by the maternal factor STELLA, while DNA methyltransferases fine-tune methylation via de novo pathways. Mutations in these reprogramming modulators are linked to clinical disease, and embryos produced in vitro frequently display epigenetic abnormalities.
Why it matters
Elucidating TET-mediated epigenetic reprogramming clarifies how pluripotency and genomic activation are established in early embryos, highlighting pathways that may explain epigenetic errors in assisted reproduction.
Limits
The abstract contains no original empirical human data, quantitative effect estimates, or systematic review search criteria. Findings reflect generalized mammalian biology, and direct clinical diagnostic or therapeutic efficacy was not evaluated.
Cited by
- supports TET enzymes produce proteins that strip chemical modifications off DNA and are required for epigenetic age resets.